Genaera Corporation
  • About Us
  • Pipeline
  • Investors
  • Clinical Trials
  • Business Development
  • Press Room
  • Contact Us
news top
Press Room
  • Genaera Corporation Announces Initiatives to Conserve Resources to Continue Development Efforts
    May 8th, 2008
  • Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph
    April 8th, 2008
  • Genaera Corporation Announces 2007 Financial Results
    March 31st, 2008
  • Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
    March 28th, 2008
Events
  • American Diabetes Association Meeting
    New Orleans, LA
    June 6th, 2008 -- June 10th, 2008
 

Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. We have significant market opportunities with a first-in-class molecule that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes. In addition, we have a value-driven, fully out-licensed partnership with MedImmune for a second core program.

Development Pipeline - Core Assests
  • Trodusquemine (MSI-1436)
  • MEDI-528 (Anti-IL-9)

  • MSI-1436, the core internal asset of Genaera, is a clinical candidate in Phase 1 development for the treatment of obesity and has applicability in type 2 diabetes. Genaera initiated its first-in-man clinical studies in 2Q07.
  • MEDI-528 the second core asset out-licensed to MedImmune/Astra Zeneca is being evaluated in Phase 2 clinical studies with applicability in the treatment of asthma. Please refer to www.medimmune.com for status of this program.

Genaera Corporation
5110 Campus Drive
Plymouth Meeting, PA 19462
(610) 941-4020

  • About Us
  • Pipeline
  • Investors
  • Clinical Trials
  • Business Development
  • Press Room
  • Contact Us
  • Events

©2008 Genaera Corporation Inc.

Site Designed and Programmed by: Wiseacre Design